Liraglutide: the version makes a difference.

Which version is for which use?

As of September 2026, Victoza had approval for type 2 diabetes; Saxenda had approval for weight management alongside food and activity changes.

FDA-approved generic versions existed for both groups. A pharmacy could not swap a diabetes generic for a weight-treatment generic as if they were the same product.

Generic medicines are approved versions of brand medicines. That is a different category from a preparation mixed by a pharmacy.

What did the weight trial show?

In the SCALE weight trial, adults without diabetes lost an average of 8.4 kg (about 18 pounds) with liraglutide over 56 weeks.

People given injections with no active medicine lost an average of 2.8 kg (about 6 pounds) over the same 56 weeks.

The kilogram figure describes a study average, not the amount an individual can expect.

In weight trials described by the official Saxenda instructions, about 39% of adults felt sick to the stomach. Among people given injections with no active medicine, about 14% felt sick.

Its boxed warning is the strongest warning in the medicine instructions. The warning describes thyroid tumours in mice as well as rats. Whether those tumours can result from liraglutide use in people remains unknown.

The instructions rule out use if you or a family member have had medullary thyroid cancer, a rare thyroid cancer. They also rule out use if you have MEN 2, a rare illness passed down in families. A past serious allergy to the medicine’s ingredients also rules it out.

What needs a supply plan?

As of September 2026, liraglutide injection was on FDA’s shortage list. Some generic versions were listed as available.

FDA’s records also listed Saxenda for discontinuation in January 2027.

Approval of a generic does not confirm that it is stocked locally.

Ask what the prescriber will do if the exact product cannot be filled. Include that question in the follow-up plan.